Skip to main content
Premium Trial:

Request an Annual Quote

New Products

Devyser Thalassemia v2

Devyser has launched the Devyser Thlassemia v2 research-use-only next-generation sequencing assay to screen for comprehensive genetic testing of alpha and beta thalassemia. The assay detects all relevant alpha and beta thalassemia variants in the HBA1/2, HBB, HBD, and HBG1/2 genes, along with copy number variations, complex variants, and additional beta modifiers.

Datar Cancer Genetics Target-MRD

Datar Cancer Genetics has launched Target-MRD, an advanced molecular residual disease (MRD) monitoring blood test for solid organ cancers. The test uses both tumor-agnostic next-generation sequencing and tumor-informed, patient-customized droplet digital PCR.

Laboratory Corporation of America: MS Monitoring Profile

Laboratory Corporation of America has launched its MS Monitoring Profile test, which combines the measurement in blood of the biomarkers neurofilament light chain and glial fibrillary acidic protein to help neurologists monitor and manage multiple sclerosis.

Oxford Gene Technology SureSeq Myeloid MRD panel

Oxford Gene Technology has launched its new next-generation sequencing-based SureSeq Myeloid MRD panel in North America. The test provides a flexible NGS workflow for the detection of ultra-low frequency biomarkers of measurable residual disease in acute myeloid leukemia.These include the largest and most complex AML-associated variants in key genes, such as large FLT3 internal tandem duplications, that often go undetected by previous generations of PCR-based enrichment technologies. OGT said its MRD panel targets 45 hotspot exons in 13 genes, with mean target coverage of up to 20,000X.

OnsiteGene XDive

OnsiteGene of San Diego has launched XDive, a real-time PCR instrument that completes 40 thermal cycles and real-time fluorescent imaging in five minutes. The company said XDive can process up to 16 samples per run with four optical channels and support up to 64 multiplexing targets. The platform is manufactured in an ISO13485-certified facility and has received US Food and Drug Administration Emergency Use Authorization for COVID-19 and monkeypox testing from both swab and saliva samples. The platform also uses a superfast master mix provided in a dried form for storage at room temperature that has a six-month shelf life. OnsiteGene said it is seeking global distributors, licensing opportunities, and collaboration partners for XDive.

The Health Alliance Bird Flu (Avian Influenza) Assay

The Health Alliance has launched its Bird Flu (Avian Influenza) Assay for the detection of infections in humans with H5N1 avian influenza virus. The firm said it developed the PCR-based assay through a collaboration with Thermo Fisher Scientific and validated it in one of the Health Alliance's national labs.

Eurofins Viracor Chagas Disease qPCR Test

Eurofins Viracor has launched a qPCR assay for Trypanosoma cruzi, the pathogen that causes Chagas disease. The test incorporates a preanalytical process designed to reduce testing delays and minimize instances of testing not performed, and the company said that it can provide results within 48 hours of sample receipt. The test supports early diagnosis and monitoring of Chagas disease, particularly in high-risk populations such as transplant recipients, where timely detection is critical to preventing disease progression or reactivation, the company said. The test has not been cleared or approved for diagnostic use by the US Food and Drug Administration.

Tempus xT CDx

Tempus AI has launched the next-generation sequencing-based xT CDx test. The US Food and Drug Administration-approved test comprises 648 genes and is used to provide solid tumor profiling in cancer patients with solid malignant neoplasms. It detects single- and multi-nucleotide variants, insertions, and deletions and microsatellite instability status from formalin-fixed, paraffin-embedded tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens. The companion diagnostic test is intended to identify patients who may benefit from treatment with certain targeted therapies.

Rapid Infection Diagnostic: BSIDx

Canadian infectious disease test firm Rapid Infection Diagnostics has launched the BSIDx, a testing system for bloodstream infections. With a single button push, users can use the instrument to identify disease-causing organisms as well as perform antibiotic susceptibility testing from positive blood cultures. Results can be achieved in five hours or less, the Calgary, Alberta-based firm said. The metabolomics-based BSIDx platform was developed in partnership with Alberta Precision Laboratories.

Anbio Biotechnology Dry Chemiluminescence Immunoassay Solution ADL-1000

Anbio Biotechnology has launched its Dry Chemiluminescence Immunoassay Solution ADL-1000. The platform was developed to deliver rapid, reliable, and cost-effective diagnostic results, the Frankfurt-based company said, adding it eliminates the need for cold chain logistics and incorporates onboard separation technology while delivering results for critical assays within 15 minutes. In addition to traditional chemiluminescence applications, the platform supports advanced diagnostics including stroke, Alzheimer's disease, thrombosis, and pre-eclampsia, Anbio said.